Aegis Keeps BioLineRx (BLRX) at 'Buy'; Plenty of Catalysts Happening Over Next 12 Months

Go back to Aegis Keeps BioLineRx (BLRX) at 'Buy'; Plenty of Catalysts Happening Over Next 12 Months

Biolinerx (BLRX) Posts Q1 Loss of 1c/Share

May 20, 2014 7:04 AM EDT

Biolinerx (NASDAQ: BLRX) reported Q1 EPS of ($0.01), $0.10 better than the analyst estimate of ($0.11).

For earnings history and earnings-related data on Biolinerx (BLRX) click here.

... More